ClinicalTrials.gg
CompletedNCT05813925Updated Jan 22, 2026

A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

A Phase 3 interventional study of Cagrilintide and Semaglutide in Obesity or Overweight, sponsored by Novo Nordisk A/S. Completed at 28 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 10 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jan 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
331
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing cagrilintide in Obesity — 9 open to participants now, 15 under way, 9 of them phase 3. cagrilintide · Obesity.

Enrollment
11th of 36
331 · median 154
Started
2023
with 4 others
Phase 3
15 of 36
4 open now
Registered
12th of 36
by date
Lead sponsor
36 of 36
Novo Nordisk A/S

Among the 36 studies testing cagrilintide in Obesity, this one is the 11th largest by enrollment, is one of 5 that started in 2023, is one of 15 in phase 3, and was the 12th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 36 studies testing cagrilintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About cagrilintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cagrilintide in Obesity, or all of them as a file.
02

Study summary

This study will look at how well the new medicine CagriSema helps people with excess body weight lose weight compared to another medicine, semaglutide. The participants will receive one injection once a week. The study medicine will be injected with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1½ years.

03

Conditions studied

  • Obesity or Overweight
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • Age greater than to or equal 18 years at the time of signing
  • a) (BMI) greater than or equal to 27.0 kilograms per square meter (kg/m\^2) with greater than or equal to 2 obesity-related complications or b) BMI greater than or equal to 35.0 kg/m\^2 with greater than or equal to 1 obesity-related complication. At least one complication should be hypertension, dyslipidaemia or T2D

Diabetes-related for participant with T2D

  • Diagnosed with T2D greater than or equal to 180 days before screening
  • 7.0-10.0 percent (53-86 millimoles per mole [mmol/mol]) (both inclusive) as measured by central laboratory at screening
  • Treatment with either lifestyle intervention, or treatment with 1-3 marketed oral antidiabetic drugs (OAD)s (metformin, α-glucosidase inhibitors [AGI], glinides, sodium-glucose cotransporter 2 inhibitor [SGLT2i]), thiazolidinediones, or sulphonylureas [SU] as a single agent or in combination) according to local label
  • Treatment with oral antidiabetic drugs should be stable (same drug(s), dose and dosing frequency) for at least 90 days before screening

Exclusion criteria

Exclusion Criteria:

Obesity-related

- Treatment with any medication prescribed for the indication of obesity or weight management within 90 days before screening

Glycaemia-related for participant without T2D

  • greater than or equal to 6.5 percent (48 mmol/mol) as measured by the central laboratory at screening
  • History of type 1 or type 2 diabetes

Diabetes-related for participant with T2D

  • Renal impairment with estimated (eGFR) lesser than 30 milli liter per min/1.73 meter square (mL/min/1.73 m\^2) as measured by central laboratory at screening
  • or severe hypoglycaemia within 6 months of screening or history of hypoglycaemia unawareness
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
331 participants (actual)

Study arms

  • Experimental
    CagriSema 2.4 mg/2.4 mg

    Participants will receive 2.4 milligrams (mg) cagrilintide and 2.4 mg semaglutide subcutaneously (s.c.) once-weekly (OW) after a dose escalation period of 16 weeks (0.25 mg of cagrilintide and 0.25 mg of semaglutide from weeks 0-4, 0.5 mg of cagrilintide and 0.5 mg of semaglutide from weeks 5-8, 1 mg of cagrilintide and 1 mg of semaglutide from weeks 9-12 and 1.7 mg of cagrilintide and 1.7 mg of semaglutide from weeks 13-16) during the maintenance period for 52 weeks

    Drug: Cagrilintide · Drug: Semaglutide

  • Active comparator
    Semaglutide 2.4 mg

    Participants will receive semaglutide s.c. 2.4 mg and placebo matched to semaglutide OW after a dose escalation period of 16 weeks (0.25 mg for weeks 0-4, 0.5 mg for weeks 5-8, 1 mg for weeks 9-12 and 1.7 mg for weeks 13-16) during the maintenance period for 52 weeks

    Drug: Semaglutide · Drug: Placebo Semaglutide

Interventions

  • Participants will receive 2.4 mg cagrilintide s.c. OW after a dose escalation period of 16 weeks for 52 weeks

  • Participants will receive 2.4 mg semaglutide s.c. OW after a dose escalation period of 16 weeks for 52 weeks

  • DrugPlacebo Semaglutide

    Participants will receive placebo matched to semaglutide

06

What researchers measure

Primary outcomes

  1. Relative Change in Body Weight

    Measured in percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 68)

Secondary outcomes

  1. Number of Participants Who Achieve (Yes/No): Body Weight Reduction Greater Than or Equal to 20 Percent

    Measured as count of participants

    Time frame: From baseline (week 0) to end of treatment (week 68)

  2. Change in Waist Circumference Measured According to Japan Society for the Study of Obesity (JASSO) Guideline

    Measured in centimeter (cm)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  3. Change in Visceral Fat Area (VFA) Measured by CT Scan in Subset of the Japanese Study Population

    Measured as percentage point

    Time frame: From baseline (week 0) to end of treatment (week 68)

  4. Change in VFA Measured by CT Scan in Subset of the Japanese Study Population

    Measured in centimeter square (cm\^2)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  5. Number of Participants Who Achieve (Yes/No): VFA lesser than 100 cm^2 (Only for Participants with VFA greater than or equal to 100 cm^2 at Baseline)

    Measured as count of participants

    Time frame: From baseline (week 0) to end of treatment (week 68)

  6. Number of Participants Who Achieve (Yes/No): Body Weight Reduction Greater Than or Equal to 25 Percent

    Measured as count of participants

    Time frame: From baseline (week 0) to end of treatment (week 68)

  7. Number of Participants Who Achieve (Yes/No): Body Weight Reduction Greater Than or Equal to 15 Percent

    Measured as count of participants

    Time frame: From baseline (week 0) to end of treatment (week 68)

  8. Number of Participants Who Achieve (Yes/No): Body Weight Reduction Greater Than or Equal to 10 Percent

    Measured as count of participants

    Time frame: From baseline (week 0) to end of treatment (week 68)

  9. Relative Change in Body Weight

    Measured in percentage (%)

    Time frame: From baseline (week 0) to week 20

  10. Change in Body Weight

    Measured in kilogram (kg)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  11. Change in Body Mass Index (BMI)

    Measured in kilogram per meter square (kg/m\^2)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  12. Change in Glycated Haemoglobin (HbA1c)

    Measured in percentage points

    Time frame: From baseline (week 0) to end of treatment (week 68)

  13. Change in Fasting Plasma Glucose (FPG)

    Measured as millimole per liter (mmol/L)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  14. Change in Fasting Insulin

    Measured as milliunits per liter (mU/L)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  15. Change in Systolic Blood Pressure (SBP)

    Measured in millimeter of mercury (mmHg)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  16. Change in Diastolic Blood Pressure (DBP)

    Measured in millimeter of mercury (mmHg)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  17. Change in Total Cholesterol

    Measured in percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  18. Change in High-Density Lipoprotein (HDL) Cholesterol

    Measured in percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  19. Change in Low-Density Lipoprotein (LDL) Cholesterol

    Measured in percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  20. Change in Very Low-Density Lipoprotein (VLDL)

    Measured in percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  21. Change in Triglycerides

    Measured in percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  22. Change in Free fatty Acids

    Measured in percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 68)

  23. Change in Impact of Weight on Quality of Life-Lite for clinical trials (IWQOL-Lite-CT) Physical Function Score

    IWQOL-Lite-CT is a 20-item patient reported outcome (PRO) instrument used to assess the impact of body weight changes in obesity studies on patient's physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score

    Time frame: From baseline (week 0) to end of treatment (week 68)

  24. Number of Treatment-Emergent Adverse Events (TEAEs)

    Measured as count of events

    Time frame: From baseline (week 0) to end of study (week 75)

  25. Number of Serious Adverse Events (SAEs)

    Measured as count of events

    Time frame: From baseline (week 0) to end of study (week 75)

07

Study locations

28 sites
  • Seino Internal Medicine Clinic_Internal medicine
    Koriyama-shi, Fukushima, Fukushima, Japan 963-8851, Japan
  • Tsuruma Kaneshiro Diabetes Clinic_Internal medicine
    Yamato-shi, Kanagawa 242-0004, Japan
  • Tsuruma Kaneshiro Diabetes Clinic
    Yamato-shi, Kanagawa 242-0004, Japan
  • Heiwadai Hospital_Internal Medicine
    Miyazaki, Miyazaki 880-0034, Japan
  • OCROM Clinic_Internal medicine
    Suita-shi, Osaka 565-0853, Japan
  • Yao Tokushukai General Hospital_Cardiovascular division
    Yao-shi, Osaka 581-0011, Japan
  • TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology
    Aichi, 468-0009, Japan
  • The University of Tokyo Hospital, Diabetes and Metabolic
    Bunkyo-ku, Tokyo, 113-8655, Japan
  • Akaicho Clinic
    Chiba-shi, Chiba, 260-0804, Japan
  • Suidoubashi Medical Clinic_Internal Medicine
    Chiyoda-ku, Tokyo, 101-0065, Japan
  • The Institute of Medical Science, Asahi Life Foundation_Internal Medicine
    Chuo-ku, Tokyo, 103-0002, Japan
  • The Institute of Medical Science, Asahi Life Foundation
    Chuo-ku, Tokyo, 103-0002, Japan
  • Okabe Clinic
    Chuo-ku, Tokyo, 104-0061, Japan
  • Kawada Clinic
    Gunma, 373-0036, Japan
  • Naka Kinen Clinic_Internal medicine
    Ibaraki, 311-0113, Japan
  • Naka Kinen Clinic
    Ibaraki, 311-0113, Japan
  • Iwate Medical University Uchimaru Medical Center, Division of Diabetes and Metabolism and Endocrine medicine
    Numakunai, 020-8505, Japan
  • Osaka NISHI-UMEDA Clinic_Internal Medicine
    Osaka, 530-0001, Japan
  • Osaka NISHI-UMEDA Clinic
    Osaka, 530-0001, Japan
  • Shinsapporo Seiryou Hospital, General Clinical Department
    Sapporo-shi, Hokkaido, 004-0004, Japan
  • Shinden Higashi Clinic_Internal medicine
    Sendai-shi, Miyagi, 983-0039, Japan
  • Shinden Higashi Clinic
    Sendai-shi, Miyagi, 983-0039, Japan
  • Tokyo-Eki Center-building Clinic_Internal Medicine
    Tokyo, 103-0027, Japan
  • Fukuwa Clinic_Internal Medicine
    Tokyo, 104-0031, Japan
  • Fukuwa Clinic
    Tokyo, 104-0031, Japan
  • ToCROM Clinic_Internal Medicine
    Tokyo, 160-0008, Japan
  • Minamino Cardiovascular Hospital_Cardiovascular medicine
    Tokyo, 192-0918, Japan
  • National Taiwan University Hospital_main
    Taipei, 100, Taiwan
08

References and documents

Publications

  • Yamauchi T, Becker NP, Hagemann CA, Huang KC, Kiyosue A, Lim S, Onishi Y, Kosuvaripalli A, Takano T, Ishigaki Y; REDEFINE 5 study group. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2026 Jun;14(6):450-462. doi: 10.1016/S2213-8587(25)00402-4. Epub 2026 Apr 17. PubMed 42009015 ↗

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Jan 2025, 21 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 21 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2023
First posted
Apr 14, 2023
StartActual
Apr 3, 2023
Primary completionActual
Jan 17, 2025
CompletionActual
Mar 7, 2025
Results delay requested
Jan 15, 2026
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05813925
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 14, 2023
Start date
Apr 3, 2023
Primary completion
Jan 17, 2025
Completion
Mar 7, 2025
Last update
Jan 22, 2026

Study contacts

Clinical Transparency' (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion